key: cord-0946104-joksmp0r
authors: Protonotariou, Efthymia; Mantzana, Paraskevi; Meletis, Georgios; Tychala, Areti; Kassomenaki, Angeliki; Vasilaki, Olga; Kagkalou, Georgia; Gkeka, Ioanna; Archonti, Maria; Kati, Styliani; Metallidis, Simeon; Skoura, Lemonia
title: Microbiological characteristics of bacteremias among COVID-19 hospitalized patients in a tertiary referral hospital in Northern Greece during the second epidemic wave
date: 2021-12-02
journal: FEMS Microbes
DOI: 10.1093/femsmc/xtab021
sha: 46ebcb8d118bc6d014755018eeef957991132b68
doc_id: 946104
cord_uid: joksmp0r

Northern Greece was struck by an intense second COVID-19 epidemic wave during the fall of 2020. Because of the coinciding silent epidemic of MDR organisms the handling of COVID-19 patients became even more challenging. In the present study, the microbiological characteristics of bacteraemias in confirmed cases of hospitalized COVID-19 patients were determined. Data from 1165 patients hospitalized between September and December 2020 were reviewed regarding the frequency of bloodstream infections, the epidemiology and the antibiotic susceptibility profiles of the causative bacteria. The hospital's antibiotic susceptibility data for all major nosocomial pathogens isolated from bacteremias of COVID-19 patients between September-December 2020 versus September-December 2019 bacteremias were also compared. Overall, 122 patients developed bacteremia (10.47%). The average of time interval between hospitalization date and development of bacteremia was 13.98 days. Admission to ICU occurred in 98 out of 122 patients with an average time of stay 15.85 days and 90.81% in-hospital mortality. In total, 166 pathogens were recovered including 114 Gram-negative bacteria and 52 Gram-positive cocci. Acinetobacter baumannii were the most frequent (n = 51) followed by Klebsiella pneumoniae (n = 45) and Enterococcus faecium (n = 31). Bacteremias in hospitalized COVID-19 patients were related with prolonged time of hospitalization and higher in-hospital mortality and the isolated microorganisms represented the bacterial species that were present in our hospital before the COVID-19 pandemic. Worryingly, the antibiotic resistance rates were increased compared to the pre-pandemic era for all major opportunistic bacterial pathogens. The pandemic highlighted the need for continuous surveillance of patients with prolonged hospitalization.

Since its emergence in December 2019 (Ye et al. 2020) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic accounting for more than 228,394,572 cases and 4,690,186 deaths worldwide as of 20 September 2021 (https://covid19.who.int/). As it has already been observed in previous epidemics due to respiratory viruses, bacterial secondary infections are frequent among hospitalised patients and attributed to worsening outcomes regarding patient's morbidity and mortality (MacIntyre et al. 2018) .

Secondary bacterial infections in COVID-19 are associated with prolonged ICU stay and mechanical ventilation, higher occurrence of ARDS and higher mortality (Bardi et al 2021; De Santis et al. 2021 ). Among them, bloodstream infections play a significant role with a prevalence varying from 5.5% to 40% in COVID-19 patients across different settings (Bhargava et al. 2021; Palanisamy et al. 2021 ; Bardi et al 2021; De Santis et al. 2021; Kokkoris et al. 2020 ).

The source of bacteremias is mainly attributed to pulmonary infections (Gomez-Simmonds et al. 2020; Bhargava et al. 2021) . Moreover, factors like the presence of central venous catheter (CVC), prolonged ICU stay, the use of immunosuppressants in COVID-19 treatment, such as corticosteroids, anakinra and tocilizumab, as well as the gut microbiome dysbiosis further contribute to progression to bacteraemia amongst COVID-19 patients (Nori et al. 2021; De Santis et al. 2021; Khatri et al. 2021; Venzon et al. 2021) . The present study aims to assess the prevalence, frequency and distribution of microorganisms as well as their antimicrobial susceptibility in confirmed cases of COVID-19 patients with bacteremia hospitalized in our institution.

We conducted a retrospective observational study of COVID-19 patients admitted and Acinetobacter baumannii OXA-23 and OXA-51 carbapenemases. rates have been documented (Nori et al. 2021) . Bloodstream infections (BSI) seem to be very frequent among mechanically ventilated COVID-19 patients (Risa et al. 2021) together with upper respiratory tract bacterial and fungal superinfections (Mazzariol et al. 2021) . A recent multicenter study from Italy showed that BSIs were a common secondary infection and were more frequent during the pandemic than in the same pre-COVID-19 time period (Pasquini et al. 2021 ).

In 2020 we observed a notable rise in BSIs accompanied by more resistant phenotypes of the isolated bacteria when compared with the respective rates of the previous year.

Notably, this variability of the resistance rates could not be explained as part of an expected year-to-year variability happening even before the pandemic. Moreover, the incidence of BSIs in COVID-19 patients in our hospital was one of the highest published in literature whereas the more prevalent causative agents among them were Gram negative bacteria, the majority of which were MDROs.

In our study, BSIs occurred in 122/1165 (10.47%) COVID-19 patients, which is in agreement with recent studies where the occurrence varied from 8.6 to 9.05% (Bhargawa Pasquini et al. 2021) , showing that BSIs are common complications in this category of patients and is higher than the reported 3-3.5% percentage in early studies (Sepulveda et al. 2020) . The microorganisms responsible for secondary infections in Our study has several limitations. First of all, it is a single center study and the implicated bacteria might represent a site-specific pathogen profile. Second limitation is the lack of detailed clinical data regarding the source of infection, type of antibiotic treatment and immunomodulators. No genomic analysis for epidemiologic association was performed, as this was beyond the scope of our study.

Despite these limitations, our study is the first to our knowledge, that gives the prevalence and spectrum of secondary bacterial bloodstream infections in Greece including a large number of patients and comparing data with those retrieved at the same period one year ago. This way, we aspired to present a notable insight into the impact of the pandemic on bloodstream infections and bacterial resistance rates among hospitalized patients in our region. Overall, our study has revealed high rates of MDRO escape BSIs among the hospitalized COVID-19 patients a finding with significant implications for active surveillance and reinforcement of hospital infection prevention practices as well as

for clinical management with the appropriate antibiotic therapies for secondary infections during the ongoing COVID-19 pandemic.

None declared. Part of the study was presented at the 31st ECCMID conference. 

Acinetobacter baumannii complex 51 51

Klebsiella pneumoniae 45 43

Pseudomonas aeruginosa 9 4

Acinetobacter junii 1 0

Klebsiella oxytoca 1 0

Enterobacter cloacae complex 2 2

Proteus mirabilis 1 0

Citrobacter koseri 1 0

Achromobacter xylosoxidans 1 1

Sphingomonas paucimobilis 1 0

Enterococcus faecalis 16 1

Enterococcus gallinarum 1 0

Streptococcus mitis 1 0

Total 166 113

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

High rate of multidrug-resistant organisms (MDROs) among COVID-19 patients presenting with bacteremia upon hospital admission

The microbial coinfection in COVID-19

Performance Standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Document M100-S25

Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: results of a prospective observational multicenter study

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and metaanalysis

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge

Clinical profile of bloodstream infections in COVID-19 patients: a retrospective cohort study

Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study

Increase in hospital-acquired carbapenem-resistant

Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions-New Jersey

Modified CLSI extended-spectrum β-lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various β-lactamases

AMR Direct Flow Chip Kit" DNA microarray for detecting antimicrobial resistance genes directly from rectal and nasopharyngeal clinical samples upon ICU admission

Acinetobacter baumannii infections in times of COVID-19 pandemic

Characterization of secondary bacterial infections and antibiotic use in mechanically ventilated patients with covid-19 induced acute respiratory distress syndrome

Secondary infections in mechanically ventilated patients with COVID-19: An overlooked matter?

Bacteremia and blood culture utilization during COVID-19 surge in New York City

A simple phenotypic method for the differentiation of metallo-b-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates

Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation

Coinfections among hospitalized patients with covid-19 in the first pandemic wave